Immuno Research Inc.
TSX VENTURE : IRI

August 01, 2006 20:04 ET

Immuno Research Inc. Announces AGM Results

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Aug. 1, 2006) - John Mason, President and CEO of Immuno Research Inc. (TSX VENTURE:IRI), is pleased to announce the voting results from the annual general meeting of Friday, July 21, 2006. The following key matters were passed:

1) Approval of the private placement with Lakota Research International for $2 million dollars. As a result of this private placement, Lakota will hold more than 20 percent interest in Immuno.

2) Approval of a corporate name change from Immuno Research Inc. to IRI Separation Technologies Inc. Formal proceedings will begin immediately and the name change will be announced once finalized.

3) Approval to increase the board of directors to five. The following directors were elected for the year 2006-2007:



John Mason President and CEO
Rick Stiksma Chief Financial Officer
Steven Pettigrew Corporate Secretary and Audit Committee
Rick Stewart Director and Audit Committee
Jimmy Cheung Director and Audit Committee


4) Approval of a company stock option plan as set out in the information circular dated June 16th, 2006.

"I am very pleased with the results of our AGM and the support shown by our shareholders. With these matters decided, Immuno is ready to move forward with developing our nutraceutical and biotechnology businesses, including the fulfillment of the five-year sales contract with Lakota," said John Mason, President and CEO. "It is also exciting to begin the process of re-branding Immuno to more clearly define the company in the marketplace."

Immuno Research will now proceed with the following initiatives:

1) Closing of the Lakota Research International private placement.

2) Integration and closing of the acquisition of certain assets from a group of vendors known as the "Alberta Group", that was announced in May 2006 (see news release dated May 30, 2006).

About Immuno Research Inc.

Immuno Research Inc. (TSX VENTURE:IRI) is a biotechnology company that specializes in the extraction, development and commercialization of monoclonal and polyclonal immunoglobulin antibodies for virus and bacteria related health issues. Intended for use as a nutraceutical for human consumption, the antibodies are derived from bovine whey and chicken eggs. The immunoglobulin antibodies are intended for both the general and specific antibody market.

On behalf of the Board of Directors, John Mason, President and CEO

Certain statements included in this news release may be "forward-looking statements" as defined in securities legislation in the United States and certain jurisdictions in Canada. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. There can be no assurances that the expectations reflected in such forward-looking statements will prove to have been correct, although they are currently believed to be reasonable. Management cautions that forward-looking statements are not guarantees and that actual results could differ materially from those expressed or implied in the forward-looking statement. Please refer to our publicly filed documents for a more complete discussion of risk factors to which our company is subject. All forward-looking statements herein are expressly qualified in their entirety by this cautionary statement. Immuno disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • Ascenta Capital Partners Inc.
    Jim Glass
    Investor Relations
    (604) 684-4743 ext. 25 or Toll Free: 1-866-684-4743 ext. 25
    jim@ascentacapital.com
    or
    Immuno Research Inc.
    John Mason
    Vancouver Office
    (604) 807-8694
    (604) 926-1485 (FAX)
    jmason99@shaw.ca